NGNeurogene Inc. NGNE · NASDAQ
$24.28 -6.90% (-$1.80)
- Market cap
- $383.7M
- Enterprise value
- $279.5M
- P/E
- -
- Forward P/E
- -
- PEG
- -
- P/S
- -
- P/FCF
- -
- EV/EBITDA
- -
- ROIC
- -53.7%
- Bruto marža
- -
- Neto marža
- -
- Dividend yield
- -
- Payout ratio
- -
- Neto dolg/EBITDA
- -
- Beta
- 2.09
- Free float
- 79.3%
O podjetju
Neurogene Inc. is an American biopharmaceutical company focused on the development of innovative therapies for the treatment of genetic neurological disorders. The company specializes in researching and developing gene therapy-based drugs that have the potential to treat and improve the lives of patients with genetically inherited neurological disorders.
Sector
Healthcare
Industry
Biotechnology
CEO
Rachel L. McMinn
Employees
131
Headquarters
New York City
Vrednotenje
Je današnja cena primerna?
Rast in ocene
Ali podjetje raste in kaj sledi?
Donosnost in kakovost
Koliko prihodkov ostane in kako dobro podjetje uporablja kapital?
Finančno zdravje
Ali zmore svoj dolg?
Kapital in dividende
Kaj podjetje počne z zasluženim denarjem?
Analitiki
Kaj menijo strokovnjaki in ali se to spreminja?
Lastniki in insajderji
Kdo ima delnice in kaj počne vodstvo?
Segmenti
Kateri del podjetja raste?
Primerjava s konkurenco
Kako se primerja s podobnimi podjetji?
Cena in tveganje
Kako se delnica obnaša?
Izkazi
Vse številke